Owing to enhanced toxicity studies, demand for novel technologies in cell analysis is increasing rapidly across the globe. Instruments with enhanced cell imaging and analysis are preferred for early as well as later stages of the drug discovery process. This is expected to fuel the demand for High Content Screening (HCS) instruments in the near future. Also, increasing government support for life sciences research and increasing progress towards establishment of innovation and research-based biotechnology industries, primarily in countries such as China and India, is expected to contribute towards increased growth rate during the forecast period.
Cell Analysis Instrumentation Market Value Forecast
The global cell analysis instrumentation market is estimated to account for US$ 1,174.1 Mn by 2015 end and is expected to reach US$ 2,120.5 Mn by 2025 at a CAGR of 6.1% during the forecast period.
HIGH CONTENT SCREENING (HCS) Market Value and Volume Forecast
In terms of revenue, the global High Content Screening (HCS) market is currently witnessing major contribution from mid-end and high-end instruments. In addition, research and development on software is likely to fuel market growth during the forecast period. Also, High Content Screening (HCS) installation globally is expected to reach 988 units by the end of 2025, registering a CAGR of 6.6% from 2015 to 2025.
Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-426
On the basis of product, High Content Screening (HCS) market segmentation includes cell imaging and analysis equipment, consumables, software and services. Cell imaging and analysis equipment is further segmented as High Content Screening (HCS) instruments, flow cytometers. Also, High Content Screening (HCS) instruments are sub-segmented into high-end High Content Screening (HCS) instruments, mid-end High Content Screening (HCS) instruments and low-end High Content Screening (HCS) instruments. The consumables segment is further sub-segmented as reagents and assay kits, Microplates and other consumables. Among the various segments, software is expected to record highest CAGR of 6.6% during the forecast period. In addition, cell imaging and analysis equipment segment is expected to dominate the market, accounting for 38.4% of the total market.
There has been an increased focus on secondary screening of cells in recent years. This is due to growing concerns of companies for toxicity studies across the globe. Furthermore, risk assessment of critical diseases is gaining importance for drug discovery across pharmaceutical and biotechnology companies. Thus, development of solutions, which offer high sensitivity in detecting problems as critical as hepatoxicity is expected to drive the demand for High Content Screening (HCS) instruments. Although, prices of High Content Screening (HCS) instruments are higher as compared to flow cytometers, availability of these instruments across educational institutions is expected to increase during the forecast period. In order to offer comprehensive offerings to lab services, manufactures need to develop such instruments. Also, there has been an increase in development of automated systems to analyse cell separation and scalability. Demand for efficient purification protocols for therapeutic cells is expected to fuel demand for high-end screening system in the next five to six years.
By Application Analysis
The High Content Screening (HCS) instruments are used for applications, such as primary and secondary screening, toxicity studies, compound profiling, target identification and validation and others. Among all these segments, toxicity studies is expected to record highest CAGR of 7.1% during the forecast period. Primary and secondary screening, and target identification and validation segments collectively are expected to account for around 63.2% of the total High Content Screening (HCS) market by 2025.
By Industry Analysis
The High Content Screening (HCS) instruments are being widely used by end-use sectors, such as pharmaceutical and healthcare, educational institutions, independent contract research organisations, government organisations, biotechnology companies and others. Among all these segments pharmaceutical and healthcare segments is expected to dominate the market in terms of revenue share contribution, registering a CAGR of 6.0% during the forecast period. Biotechnology companies are expected to witness increased installation of high content screening instruments, thus registering highest CAGR of 7.0% during the forecast period.
Asia Pacific Excluding Japan Most Lucrative Market for High Content Screening (HCS) Market
Geographically, the global High Content Screening (HCS) market analysis focusses on North America, Latin America, Eastern Europe, Western Europe, Japan, Asia Pacific Excluding Japan (APEJ), Japan and Middle East and Africa (MEA). In terms of market share contribution, North America represents the most lucrative market, followed by Western Europe and APEJ. North America is expected to register a CAGR of 6.0% accounting for US$ 673.5 million by 2025. In Asia Pacific, China and India owe a significant contribution to growth of Asia Pacific High Content Screening (HCS) market and thus, represent opportunities for manufacturers in the near future. APEJ is expected to record highest CAGR of 7.0% during the forecast period. Japan records comparatively less growth. This is due to high entry barriers for international players to enter the Japan High Content Screening (HCS) market.
Send An Enquiry@ http://www.futuremarketinsights.com/askus/rep-gb-426
Competitive Players Outlook
Since the market for High Content Screening (HCS) instruments is consolidated in nature, major players across the globe are focussed on developing new product offerings across various products, which includes instruments, consumables, software and services for cell analysis. This ensures sustainability in the long run and restricts new entrants from entering the market. The global High Content Screening (HCS) market competitive landscape includes Becton, Dickinson and Company (BD), Thermo Fisher Scientific Inc., GE Healthcare, Olympus Corporation, PerkinElmer Inc., Merck Millipore Corporation, Danaher Corporation (Molecular Devices), Yokogawa Electric Corporation, Sysmex Corporation and Thorlabs Inc.